Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Humacyte (HUMA) EPS (Basic) (2024 - 2025)

Humacyte has reported EPS (Basic) over the past 2 years, most recently at -$0.15 for Q4 2025.

  • Quarterly results put EPS (Basic) at -$0.15 for Q4 2025, up 6.25% from a year ago — trailing twelve months through Dec 2025 was -$0.22 (up 82.54% YoY), and the annual figure for FY2025 was -$0.26, up 79.37%.
  • EPS (Basic) for Q4 2025 was -$0.15 at Humacyte, down from -$0.11 in the prior quarter.
  • Over the last five years, EPS (Basic) for HUMA hit a ceiling of $0.28 in Q1 2025 and a floor of -$0.48 in Q2 2024.